PCM
CYTK icon

Peregrine Capital Management’s Cytokinetics CYTK Stock Holding History

Peregrine Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.52M Sell
100,019
-3,607
-3% -$259K 0.28% 114
2026
Q1 		$6.83M Sell
103,626
-4,436
-4% -$282K 0.25% 118
2025
Q4 		$6.87M Sell
108,062
-46,387
-30% -$2.89M 0.21% 136
2025
Q3 		$8.49M Sell
154,449
-4,079
-3% -$168K 0.26% 106
2025
Q2 		$5.24M Buy
158,528
+2,791
+2% +$97.1K 0.16% 192
2025
Q1 		$6.26M Buy
155,737
+5,394
+4% +$248K 0.21% 144
2024
Q4 		$7.07M Buy
150,343
+9,432
+7% +$490K 0.21% 135
2024
Q3 		$7.44M Buy
140,911
+310
+0.2% +$17.3K 0.22% 118
2024
Q2 		$7.62M Buy
140,601
+14,208
+11% +$858K 0.22% 141
2024
Q1 		$8.86M Sell
126,393
-5,121
-4% -$396K 0.25% 105
2023
Q4 		$11M Sell
131,514
-73,150
-36% -$2.65M 0.33% 60
2023
Q3 		$6.03M Buy
204,664
+23,936
+13% +$797K 0.18% 219
2023
Q2 		$5.9M Sell
180,728
-18,688
-9% -$691K 0.16% 232
2023
Q1 		$7.02M Buy
199,416
+39,273
+25% +$1.6M 0.2% 216
2022
Q4 		$7.34M Buy
160,143
+11,309
+8% +$487K 0.23% 202
2022
Q3 		$7.21M Sell
148,834
-25,659
-15% -$1.23M 0.23% 200
2022
Q2 		$6.86M Sell
174,493
-45,047
-21% -$1.81M 0.21% 217
2022
Q1 		$8.08M Buy
219,540
+3,160
+1% +$112K 0.19% 217
2021
Q4 		$9.86M Sell
216,380
-72,116
-25% -$2.78M 0.2% 203
2021
Q3 		$10.3M Sell
288,496
-135,679
-32% -$3.99M 0.21% 205
2021
Q2 		$8.39M Sell
424,175
-22,379
-5% -$525K 0.15% 246
2021
Q1 		$10.4M Sell
446,554
-109,130
-20% -$2.33M 0.19% 228
2020
Q4 		$11.5M Buy
+555,684
New +$10.2M 0.22% 214

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Peregrine Capital Management's CYTK Position: Q2 2026 in Review

Peregrine Capital Management reduced its Cytokinetics (CYTK) stake by 3.5% in Q2 2026, selling an estimated $259K and leaving 100,019 shares worth $8.52M. The position accounts for 0.28% of the portfolio, ranked #114.

Peregrine Capital Management first reported a position in CYTK in Q4 2020 and has held it in 23 quarters since. The position peaked at $11.5M in Q4 2020. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Peregrine Capital Management held 100,019 shares of Cytokinetics worth $8.52M as of Q2 2026.
  • Peregrine Capital Management sold 3,607 Cytokinetics shares in Q2 2026, an estimated $259K.
  • Cytokinetics made up 0.28% of Peregrine Capital Management's portfolio in Q2 2026, its #114 holding.
  • Peregrine Capital Management first reported a position in Cytokinetics in Q4 2020 and has held it in 23 quarters since.
  • Peregrine Capital Management's Cytokinetics position peaked at $11.5M in Q4 2020.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Peregrine Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.